Inhibition of sPLA.sub.2-IIA Prevents LPS-Induced Neuroinflammation by Suppressing ERK1/2-cPLA.sub.2[alpha] Pathway in Mice Cerebral Cortex

Neuroinflammation is involved in various central nervous system (CNS) disorders, including brain infections, ischemia, trauma, stroke, and degenerative CNS diseases. In the CNS inflammation, secretory phospholipase A.sub.2 -IIA (sPLA.sub.2 -IIA) acts as a mediator, resulting in the generation of the...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2013-10, Vol.8 (10), p.e77909
Main Authors: Xiang, Yanxiao, Chen, Lin, Liu, Huiqing, Liu, Xiaoqian, Wei, Xinbing, Sun, Baozhu, Wang, Tian, Zhang, Xiumei
Format: Article
Language:English
Subjects:
Brain
Health aspects
Inflammation
Ischemia
Phospholipases
Prevention
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neuroinflammation is involved in various central nervous system (CNS) disorders, including brain infections, ischemia, trauma, stroke, and degenerative CNS diseases. In the CNS inflammation, secretory phospholipase A.sub.2 -IIA (sPLA.sub.2 -IIA) acts as a mediator, resulting in the generation of the precursors of pro-inflammatory lipid mediators, such as prostaglandins (PGs) and leukotrienes (LTs). However, the role of sPLA.sub.2 -IIA in neuroinflammation is more complicated and remains unclear yet. In the present study, we investigated the effect of sPLA.sub.2 -IIA inhibition by specific inhibitor SC-215 on the inflammation in LPS-induced mice cerebral cortex and primary astrocytes. Our results showed that the inhibition of sPLA.sub.2 -IIA alleviated the release of PGE.sub.2 by suppressing the activation of ERK1/2, cPLA.sub.2 [alpha], COX-2 and mPGES-1. These findings demonstrated that sPLA.sub.2 -IIA showed the potential to regulate the neuroinflammation in vivo and in vitro, indicating that sPLA.sub.2 -IIA might be a novel target for the treatment of acute neuroinflammation.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0077909